Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI)

Authors
Category Primary study
JournalJournal of Allergy and Clinical Immunology
Year 2020
This article has no abstract
Epistemonikos ID: 937b3c086c0b85216efee12ec991cbc2f828f3b7
First added on: Feb 11, 2025